Psychologists in Wellington, KS Accepting Medicare
6 Psychologists found. Showing 1 - 6
 Greg G Olson, LCP Psychologist - Clinical Medicare: Not Enrolled in Medicare Practice Location: 1601 W 16th St, Wellington, KS 67152 Phone: 620-326-7448 |
Richard L Gaskill, LCP, LCPC, LMLP Psychologist - Counseling Medicare: Not Enrolled in Medicare Practice Location: 1601 W 16th St, Wellington, KS 67152 Phone: 620-326-7448 |
 Jeanne Brown, LCP, LMLP Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1601 W 16th St, Wellington, KS 67152 Phone: 620-326-7448 |
Joshua Clayton Rikard Psychologist - Prescribing (Medical) Medicare: Not Enrolled in Medicare Practice Location: 717 N Olive St, Wellington, KS 67152 Phone: 813-892-5366 |
Ms. Kathleen A Terhune, LCP Psychologist - Clinical Medicare: Not Enrolled in Medicare Practice Location: 113 E Lincoln Ave, Wellington, KS 67152 Phone: 620-326-6373 |
Tasia K Farley, LMLP Psychologist - Counseling Medicare: Not Enrolled in Medicare Practice Location: 1601 W 16th St, Wellington, KS 67152 Phone: 620-326-7448 Fax: 620-326-6662 |
News Archive
Tips for recognizing stroke symptoms
Drs. Savita Khanna and Cameron Rink, both assistant professors of surgery in the College of Medicine at The Ohio State University Medical Center are part of a research team that has been working for more than a decade to identify ways to reduce brain injury during stroke.
Research findings may help scientists develop anthrax treatments for humans
Researchers at the National Institute of Allergy and Infectious Diseases and the National Heart, Lung, and Blood Institute, both part of the National Institutes of Health, have identified the cells in two distinct areas of the body that are simultaneously targeted for damage by anthrax toxins, eventually causing illness and sometimes death. Their findings, which appeared online today in Nature, are based on testing in mice.
Tarsa obtains $10 million senior credit facility to support NDA submission for Ostora tablet
Tarsa Therapeutics, Inc. today announced that it has secured a $10 million senior credit facility from Oxford Finance LLC and Square 1 Bank. The company intends to use the proceeds to support its plans to file a New Drug Application (NDA) with the U.S. Food and Drug Administration for its Ostora tablet for the treatment of postmenopausal osteoporosis, currently targeted for early 2015.
Arena Pharmaceuticals initiates patient screening for phase 1 clinical trial of APD916
Arena Pharmaceuticals, Inc. announced today the initiation of patient screening in a Phase 1 clinical trial of APD916, a novel oral drug candidate discovered by Arena that targets the histamine H3 receptor for the treatment of narcolepsy and cataplexy.
› Verified 5 days ago
Counselors
Pharmacists
Psychologists
Clinical Social Workers
Dentists
Occupational Therapists